Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Soft-tissue sarcomas exhibit significant histologic diversity with over 50 subtypes.
• Current knowledge of genomic alterations in these diverse tumors remains limited.
• Approximately 10,700 new cases and 3,800 deaths occur annually in the US.

Purpose of the Study:

• To conduct an integrative analysis of DNA sequence, copy number, and mRNA expression across seven major sarcoma subtypes.
• To identify frequently mutated genes and their clinical associations.
• To explore potential therapeutic targets based on molecular alterations.

Main Methods:

• Integrative analysis of DNA sequence, copy number, and mRNA expression data.
• Analysis of 207 tumor samples from seven major soft-tissue sarcoma subtypes.
• Gene knockdown experiments using short hairpin RNA (shRNA).

Main Results:

• Identified frequent mutations in TP53, NF1, and PIK3CA across different subtypes.
• PIK3CA mutations in myxoid/round-cell liposarcomas (MRCs) correlated with Akt activation and poor outcomes.
• NF1 mutations (point mutations and deletions) were found in myxofibrosarcomas and pleomorphic liposarcomas.
• Knockdown of amplified genes like CDK4 and YEATS4 in dedifferentiated liposarcoma reduced cell proliferation.

Conclusions:

• Provides a comprehensive molecular landscape of diverse soft-tissue sarcoma subtypes.
• Highlights PIK3CA and NF1 as key genes with significant mutations and clinical relevance.
• Suggests that targeting amplified genes such as CDK4 and YEATS4 may be a viable therapeutic strategy for specific sarcoma subtypes.